quinazolines has been researched along with Fatty Liver, Nonalcoholic in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 2 (40.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dai, Y; Shen, T; Zhou, J; Zhu, W | 1 |
| Hashiguchi, Y; Hosoyamada, K; Imamura, N; Kajiya, S; Kamada, T; Komorizono, Y; Koriyama, N; Shinmaki, H; Tsukasa, M; Ueyama, N | 1 |
| Chen, H; Hu, J; Liang, D; Liang, G; Liu, Z; Wang, J; Wang, W; Zhang, W; Zhao, L; Zhong, P | 1 |
| Choung, S; Joung, KH; Kim, HJ; Kim, JM; Ku, BJ; Lee, ES | 1 |
| Fujii, M; Klein, T; Mark, M; Sandel, J; Shibazaki, Y; Wakamatsu, K; Yoneyama, H | 1 |
1 trial(s) available for quinazolines and Fatty Liver, Nonalcoholic
| Article | Year |
|---|---|
Metformin dose increase versus added linagliptin in non-alcoholic fatty liver disease and type 2 diabetes: An analysis of the J-LINK study.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Linagliptin; Metformin; Non-alcoholic Fatty Liver Disease; Purines; Quinazolines; Treatment Outcome | 2021 |
4 other study(ies) available for quinazolines and Fatty Liver, Nonalcoholic
| Article | Year |
|---|---|
The combination of berberine and evodiamine ameliorates high-fat diet-induced non-alcoholic fatty liver disease associated with modulation of gut microbiota in rats.
Topics: Animals; Berberine; Diet, High-Fat; Gastrointestinal Microbiome; Liver; Mice; Mice, Inbred C57BL; Non-alcoholic Fatty Liver Disease; Quinazolines; Rats | 2022 |
Inhibition of EGFR attenuates fibrosis and stellate cell activation in diet-induced model of nonalcoholic fatty liver disease.
Topics: Animals; Cells, Cultured; Diet, High-Fat; Disease Models, Animal; ErbB Receptors; Hepatic Stellate Cells; Liver Cirrhosis; Male; Mice; Mice, Inbred C57BL; Non-alcoholic Fatty Liver Disease; Quinazolines; Rats; Tyrphostins | 2018 |
Epidermal growth factor receptor inhibition attenuates non-alcoholic fatty liver disease in diet-induced obese mice.
Topics: Animals; Cell Line, Tumor; Diabetes Mellitus, Experimental; Dietary Fats; ErbB Receptors; Humans; Lipogenesis; Male; Mice; Non-alcoholic Fatty Liver Disease; Quinazolines; Signal Transduction | 2019 |
Linagliptin alleviates hepatic steatosis and inflammation in a mouse model of non-alcoholic steatohepatitis.
Topics: Animals; Animals, Newborn; Autoradiography; Diet, High-Fat; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; DNA Primers; Immunohistochemistry; Interferon-gamma; Linagliptin; Mice; Non-alcoholic Fatty Liver Disease; Purines; Quinazolines; Real-Time Polymerase Chain Reaction; RNA, Messenger; Streptozocin; Suppressor of Cytokine Signaling 3 Protein; Suppressor of Cytokine Signaling Proteins; Time Factors; Tumor Necrosis Factor-alpha | 2014 |